China SXT Pharmaceuticals, Inc.
No SEC Form 4 filings for $SXTC in the last 30 days.
See all $SXTC insider activity →The Dow Jones gained 200 points, while NASDAQ and S&P 500 showed mixed results. Chipotle shares fell 4% after Starbucks denied acquisition rumors. First Tracks Biotherapeutics, J-Star Holding, and Euro Tech Holdings rose, while Service Properties Trust, China SXT Pharmaceuticals, and TTM Technologies declined. Commodities saw oil rise and gold fall. European and Asian markets also showed mixed results.
U.S. stocks were mixed on Monday, with the Dow up 0.4% and Nasdaq down 0.2%. Enovix (ENVX) shares surged after reporting a 38% year-over-year revenue increase to $11M. Other movers: MNDR +289%, YMAT +72%, CLWT +68%, DKI -51%, SXTC -35%, VIVK -34%. Oil rose 1.4%, gold fell 0.5%. European and Asian markets showed mixed results.
U.S. stocks closed higher on Friday, with the Dow Jones up 0.83%, S&P 500 up 0.59%, and Nasdaq up 0.64%. Top performers included Amazon, Cisco, and Visa, while Verizon, 3M, and Home Depot declined. Moderna and Crown Castle also saw significant gains. Oil prices fell slightly, and gold futures rose. The CBOE Volatility Index decreased by 3.70%.
Over the past 7 days, AlphAI's AI scored 9 news stories mentioning SXTC (China SXT Pharmaceuticals, Inc.). Coverage has skewed bearish: 1 bullish, 0 neutral, and 8 bearish.
Recent SXTC coverage spans market movers, financial news and corporate actions.
Dilutive financing risk from the registered direct offering likely drives downside for SXTC.
Shares declined following capital raise announcement.
Negative momentum is clear, but the article does not disclose any new company-specific negative catalyst.
The capital raise provides new cash but dilutes existing shareholders.
Likely short‑covering and speculative buying on the split and financing news.
AlphAI scores every news story that mentions SXTC with an AI model for sentiment and relevance, and aggregates insider trades from China SXT Pharmaceuticals, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
The Dow Jones gained 200 points, while NASDAQ and S&P 500 showed mixed results. Chipotle shares fell 4% after Starbucks denied acquisition rumors. First Tracks Biotherapeutics, J-Star Holding, and Euro Tech Holdings rose, while Service Properties Trust, China SXT Pharmaceuticals, and TTM Technologies declined. Commodities saw oil rise and gold fall. European and Asian markets also showed mixed results.
7 min readU.S. stocks were mixed on Monday, with the Dow up 0.4% and Nasdaq down 0.2%. Enovix (ENVX) shares surged after reporting a 38% year-over-year revenue increase to $11M. Other movers: MNDR +289%, YMAT +72%, CLWT +68%, DKI -51%, SXTC -35%, VIVK -34%. Oil rose 1.4%, gold fell 0.5%. European and Asian markets showed mixed results.
2 min readU.S. stocks closed higher on Friday, with the Dow Jones up 0.83%, S&P 500 up 0.59%, and Nasdaq up 0.64%. Top performers included Amazon, Cisco, and Visa, while Verizon, 3M, and Home Depot declined. Moderna and Crown Castle also saw significant gains. Oil prices fell slightly, and gold futures rose. The CBOE Volatility Index decreased by 3.70%.
3 min readChina SXT Pharmaceuticals (SXTC) announced a $12M registered direct offering, selling 8M shares at $1.50 each, plus warrants. The offering is expected to close on Oct 9, 2026, with Univest Securities as the placement agent. The company plans to use the proceeds for general corporate purposes.
1 min readChina SXT Pharmaceuticals (SXTC) shares surged 536% post-share consolidation, with recent financing plans. VERAXA Biotech (VRXA) rose 15% after adopting FDA-aligned methodologies. ArriVent BioPharma (AVBP) gained 12% despite a missed Phase 3 trial endpoint. SciSparc (SPRC) climbed 8% on quantum analysis advancements.
3 min readChina SXT Pharmaceuticals Inc. (SXTC) shares surged 28.78% on August 18, 2026, driven by investor optimism and speculative trading. The stock's recent volatility follows a significant price jump from $0.06–$0.12 in late July to $3–$5 in mid-August, likely due to a reverse stock split. The company reported $1.14M in revenue, $34.8M in total assets, and $28.2M in cash, with a price-to-book ratio of 0.07 and negative return on capital. Traders are focusing on the stock's volatile price action rathe
4 min readChina SXT Pharmaceuticals (NASDAQ:SXTC) shares fell 77% after it announced a $9 million registered direct offering. The company will sell 4.5 million units at $2.00 each, with each unit including one Class A share and a warrant exercisable at $3.20, expiring in one year. Closing is expected around July 24, 2025.
3 min readChina SXT Pharmaceuticals said in an SEC filing it may sell up to $100 million of Class A ordinary shares under an at-the-market program, issuing shares from time to time on Nasdaq or other venues. Univest Securities will act as sales agent and receive a 3% commission plus certain expenses. The stock closed at $1.68 (+0.60%) and rose 25.6% after hours to $2.11.
4 min readChina SXT Pharmaceuticals, Inc. (Nasdaq: SXTC) announced a share re-classification, effective March 24, 2026, which will introduce a dual-class share structure. The re-classification was approved by shareholders on July 28, 2025, establishing Class A Ordinary Shares with no par value and Class B Ordinary Shares entitling holders to fifty votes per share. Existing shares held through nominees will be automatically adjusted to reflect this change.
2 min readChina SXT Pharmaceuticals (SXTC) filed a Form 6-K on December 31, 2025, disclosing unaudited financial results for the first half of 2025, covering the period ended September 30, 2025. The company highlighted its continued reliance on a China-based VIE structure and noted significant regulatory, capital control, and tax risks that could impact its control over the VIE and its ability to remit dividends to investors. These factors pose key risks for investors and stakeholders.
3 min read
